Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL21640604

Cc1cc(NC(=O)C2CNC2)no1.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 6/20 0.46
MEN1 O00255 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 2/20 0.43
FLT3 P36888 1/20 0.43
MAPK10 P53779 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 1/20 0.43
EGFR P00533 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322149 0.79 SMN1; SMN2 (0.59) POLBTDP1SMN1; SMN2KMT2AMEN1
SCHEMBL8833289 0.79 SMN1; SMN2 (0.66) POLBTDP1SMN1; SMN2KMT2AMEN1
Trifluoroacetic Acid SCHEMBL30585801 0.79 LCK (0.45) SMN1; SMN2KMT2AMEN1MAPTNPC1
Trifluoroacetic Acid SCHEMBL21641132 0.79 LCK (0.45) SMN1; SMN2KMT2AMEN1MAPTNPC1
SCHEMBL2324701 0.78 SMN1; SMN2 (0.55) POLBTDP1SMN1; SMN2KMT2AMEN1
Trifluoroacetic Acid SCHEMBL21639934 0.78 KMT2A (0.41) POLBSMN1; SMN2KMT2ANPC1RAB9A
Trifluoroacetic Acid SCHEMBL21640546 0.76 MAPT (0.43) POLBKMT2AMEN1MAPTNPC1
Trifluoroacetic Acid SCHEMBL21640630 0.76 GSK3B (0.34) MAPTNPC1RAB9A
SCHEMBL21640605 0.74 KMT2A (0.48) POLBTDP1SMN1; SMN2KMT2AMEN1
Trifluoroacetic Acid SCHEMBL30241438 0.74 KDM5A (0.43) POLBTDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2022-03-29 US disclosed
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3604305-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF RAB10, HDAC10, NEK10 POLB 3691/4885TDP1 2912/4885SMN1; SMN2 3320/4885
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof RARA, RAB10, RABL6 POLB 3386/4885TDP1 3043/4885SMN1; SMN2 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.